What Should Your TSH Be After Thyroid Cancer Surgery?

After surgery for papillary or follicular thyroid cancer, your TSH goal is set by your cancer team, not by the lab's normal range. It depends on your risk of recurrence and on how you respond over the first one to two years: below 0.1 mU/L when risk is high, 0.1–0.5 mU/L when it is intermediate, and 0.5–2 mU/L when it is low or follow-up looks clean. (mU/L and mIU/L are the same unit.)

Why is TSH kept low after thyroid cancer surgery?

Differentiated thyroid cancer cells carry the TSH receptor. The 2015 American Thyroid Association (ATA) guideline explains that they respond to TSH by making more thyroid proteins, such as thyroglobulin, and by growing faster [C1]. Lowering TSH with a slightly higher levothyroxine dose removes part of that growth signal, with the aim of reducing recurrence [C1][C8].

The benefit is uneven. A meta-analysis cited by the guideline found suppression reduced major adverse clinical events (relative risk 0.73), and TSH below 0.1 mU/L may improve outcomes in high-risk patients. No such benefit has been documented at low risk, and going below 0.03 mU/L may add nothing [C1]. So the target follows your risk group instead of "as low as possible."

Levothyroxine therefore does two jobs: it replaces your missing hormone and holds TSH where your team wants it, a use the FDA label lists as its own indication [C5]. For the wider picture of follow-up, see life after thyroid cancer.

What TSH target does the ATA guideline recommend?

The 2015 ATA guideline sets targets right after initial therapy (Recommendation 59, by risk group) and during long-term follow-up (Recommendation 70, by response) [C1]. Its own wording is quoted where it uses a phrase.

Risk / response category	Typical TSH target in the guideline	Why
High risk, after initial therapy	Below 0.1 mU/L	Suppression below 0.1 may improve outcomes in high-risk disease (strong recommendation, moderate-quality evidence) [C1]
Intermediate risk, after initial therapy	0.1–0.5 mU/L	Milder suppression; weak recommendation, low-quality evidence [C1]
Low risk, undetectable thyroglobulin (with or without remnant ablation)	0.5–2 mU/L, "the lower end of the reference range"	No documented benefit from deeper suppression at low risk [C1]
Low risk, low-level thyroglobulin after remnant ablation	0.1–0.5 mU/L, "at or slightly below the lower limit of normal"	Some thyroid tissue may remain, so surveillance continues [C1]
Low risk after lobectomy (half the gland removed)	0.5–2 mU/L, "the mid to lower reference range"	Levothyroxine "may not be needed" if your own TSH stays there [C1]
Structural incomplete response (disease visible on imaging)	Below 0.1 mU/L "indefinitely in the absence of specific contraindications"	Known disease remains, so the growth signal is kept low [C1]
Biochemical incomplete response (thyroglobulin up, imaging clear)	0.1–0.5 mU/L	Weighed against initial risk, thyroglobulin level and trend, and suppression risk [C1]
High risk at diagnosis, now excellent or indeterminate response	0.1–0.5 mU/L "for up to 5 years", then less suppression	Caution after high-risk disease, balanced against side effects [C1]
Excellent or indeterminate response, especially low risk	0.5–2 mU/L, "the low reference range"	No documented benefit from suppression at low risk [C1]

The guideline says each goal must balance the benefit of suppression against harm from mild hormone excess [C1], so your target can sit outside this table for good reasons such as heart disease, osteoporosis or age.

How does the target change when follow-up goes well?

The ATA uses "dynamic risk stratification": your risk group from surgery is only the first estimate, and your team re-labels you as results come in [C1]. The four response categories are:

• Excellent response: negative imaging and a thyroglobulin below 0.2 ng/mL on levothyroxine, or below 1 ng/mL after TSH stimulation. Recurrence in this group is 1%–4% [C1].
• Indeterminate response: nonspecific findings on imaging, a thyroglobulin that is detectable but below 1 ng/mL on levothyroxine, or Tg antibodies that are stable or falling. About 15%–20% of this group later shows structural disease [C1].
• Biochemical incomplete response: imaging is clear, but thyroglobulin stays at or above 1 ng/mL on levothyroxine (10 ng/mL or more after stimulation), or Tg antibodies are rising [C1].
• Structural incomplete response: disease that can be seen on imaging [C1].

In the guideline's words, an excellent response "should lead to an early decrease" in follow-up intensity and in the degree of TSH suppression [C1].

The 2025 ATA guideline goes further [C2]. A published comparison of the two editions reports that it individualizes any TSH below the reference range: within the range for excellent and indeterminate responses, below it for biochemical and structural incomplete responses, with exact numbers called inconclusive [C3]. It advises against long-term suppression in low- and intermediate-risk patients with no evidence of recurrence, and asks teams to reassess targets over time [C3].

What do thyroglobulin and Tg antibodies tell your team?

Thyroglobulin (Tg) is a thyroid-specific protein. After a total thyroidectomy, and especially after radioiodine, little tissue is left to make it, so Tg works as a tumor marker [C1]. Both guidelines measure it on levothyroxine every 6–12 months in early follow-up [C1][C3]; the 2015 edition stretches this to at least 12–24 months after an excellent response at low or intermediate risk [C1].

Tg antibodies can interfere with the Tg test, so both editions measure them with every Tg test, ideally in the same laboratory with the same assay [C1][C3]. If you have antibodies, the trend becomes a marker of its own: stable or falling levels fit the indeterminate group, while rising levels count as a biochemical incomplete response [C1]. The 2025 update adds that Tg alone cannot be relied on in people with antibodies, so imaging becomes the main surveillance tool [C3]. TSH itself is checked at least every 12 months [C1].

What are the risks of keeping TSH suppressed for years?

A suppressed TSH is a mild, deliberate excess of thyroid hormone. The ATA's main concerns are worsening angina in people with ischemic heart disease, a higher risk of atrial fibrillation in older patients, and a higher risk of osteoporosis in postmenopausal women [C1].

• Bone. Among 771 low- and intermediate-risk patients followed for a median of 6.5 years, recurrence was the same with or without suppression, but women with a median TSH of 0.4 mIU/L or lower had more osteoporosis (hazard ratio 3.5). The excess risk disappeared when median TSH stayed around 1 mIU/L [C6]. A 2026 study of postmenopausal women suppressed for at least 3 years also found more osteoporosis and lower muscle mass than in comparison groups [C9]. More on this in thyroid and bone health.
• Heart rhythm. A meta-analysis of 6 observational studies (187,754 people with differentiated thyroid cancer) found atrial fibrillation about 1.5 times as often as in controls (incidence rate ratio 1.54). The authors point to long-term suppression as a possible reason, but observational data cannot prove cause [C7]. See thyroid and cardiovascular risk.

A 2026 review advises avoiding aggressive suppression where possible in osteoporosis, atrial fibrillation, coronary artery disease and older age [C8]. For postmenopausal women at risk of bone loss, the 2015 guideline says calcium, vitamin D and bone medicines should be considered [C1].

Why is my TSH high after thyroidectomy for cancer?

A TSH above target is common in the first months and usually has an ordinary explanation:

Situation	What is going on	What usually happens
Dose still being found	The label's full replacement dose is 1.6 µg/kg/day; doses change in 12.5–25 µg steps, and the full effect can take 4–6 weeks [C5]	TSH is rechecked about 6–8 weeks after each change [C5]
Preparation for radioiodine	If levothyroxine is withdrawn, it is stopped for 3–4 weeks to push TSH above 30 mIU/L on purpose [C1]	The 2025 update prefers recombinant TSH injections over withdrawal [C4]
Absorption	Food, calcium carbonate, iron, bile acid binders, antacids and proton pump inhibitors can reduce uptake [C5]	The label advises an empty stomach, 30–60 minutes before breakfast, and 4 hours from binding drugs [C5]
Missed or irregular doses	The label names poor adherence, malabsorption and drug interactions as causes of an inadequate response [C5]	Your team reviews your routine before changing the dose
Changed needs or lab interference	Body weight and pregnancy change the dose needed; biotin can distort thyroid tests [C5]	Stop biotin at least 2 days before blood tests, per the label [C5]

A high TSH before radioiodine is part of the plan (see our radioactive iodine guide). Otherwise, bring the result to your team rather than adding tablets; dose-finding is covered in life after thyroidectomy. In Thyra, you can log each TSH and Tg result to see the trend, and medication timing plans coffee, breakfast and supplement windows around levothyroxine.

When to talk to your doctor

Contact your care team if:

• A TSH result is well outside the target they gave you, high or low.
• You have palpitations, a racing or irregular heartbeat, tremor or poor sleep, which can mean too much hormone [C5].
• You feel exhausted, cold and slowed down, which can mean too little.
• You notice a new lump in your neck, a lasting change in your voice, or trouble swallowing.
• You are pregnant or planning a pregnancy, or you start a new medicine or supplement.

Chest pain, fainting or a very fast irregular heartbeat needs urgent care.

Frequently asked questions

Is a TSH of 0.01 too low after thyroid cancer surgery?

It depends on your risk group. For high-risk or visible disease, the 2015 ATA guideline aims below 0.1 mU/L, so 0.01 can be on target. At low risk with clean follow-up, it is well below the usual 0.5–2 mU/L goal and worth raising with your team [C1].

How long will my TSH be kept suppressed?

There is no single duration. After high-risk disease with an excellent response, the 2015 guideline suggests 0.1–0.5 mU/L for up to 5 years before easing [C1]. With visible disease, it can be indefinite. The 2025 update advises against long-term suppression at low or intermediate risk without evidence of disease [C3].

Why is my TSH high a few weeks after surgery?

Usually the dose is still being found: its full effect can take 4–6 weeks, and TSH is rechecked about 6–8 weeks after each change. Missed doses and taking levothyroxine with food, calcium or iron are other common reasons [C5].

Can I lower my dose myself if I get palpitations?

No. Tell your care team, who may check your TSH and decide on any change. Chest pain or a very fast irregular heartbeat needs urgent care.

Bottom line

After thyroid cancer surgery, your TSH target comes from your recurrence risk and your response to therapy: below 0.1 mU/L for high risk or visible disease, 0.1–0.5 mU/L for intermediate risk, and 0.5–2 mU/L for low risk or an excellent response [C1]. Ask your team which category you are in, what your current target is, and when it will be reviewed. If TSH comes back high, look at timing, absorption and missed doses with them, and let them make any dose change.